Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.62 |
| ▸ | ZAP70 | P43403 | 9/20 | 0.47 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298554 | 0.94 | LRRK2 (0.67) | LRRK2ZAP70JAK2TACR2SRC | |
| SCHEMBL12103864 | 0.90 | LRRK2 (0.63) | LRRK2ZAP70JAK2SRCSYK | |
| SCHEMBL12103816 | 0.90 | LRRK2 (0.63) | LRRK2ZAP70JAK2TACR2USP2 | |
| SCHEMBL12103807 | 0.89 | LRRK2 (0.77) | LRRK2JAK2TACR2SYKSLC2A1 | |
| SCHEMBL12103817 | 0.89 | LRRK2 (0.66) | LRRK2ZAP70JAK2TACR2SYK | |
| SCHEMBL12103871 | 0.89 | LRRK2 (0.61) | LRRK2ZAP70JAK2TACR2SYK | |
| SCHEMBL12103837 | 0.88 | LRRK2 (0.65) | LRRK2ZAP70JAK2TACR2SYK | |
| SCHEMBL1298562 | 0.87 | LRRK2 (0.62) | LRRK2ZAP70JAK2TACR2SYK | |
| SCHEMBL12103842 | 0.86 | LRRK2 (0.65) | LRRK2JAK2TACR2SYKSLC2A1 | |
| SCHEMBL12103849 | 0.86 | LRRK2 (0.67) | LRRK2ZAP70JAK2TACR2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404677-B2 | Kinase inhibitors | GENOSCO (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110269739-A1 | KINASE INHIBITORS | OSCOTEC, INC. (KR) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269739-A1 | KINASE INHIBITORS | JAK1, LCK, MAP3K20 | LRRK2 436/4885ZAP70 390/4885JAK2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.